Comparative Pharmacology
Head-to-head clinical analysis: VI DOM A versus VITAMIN A PALMITATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VI DOM A versus VITAMIN A PALMITATE.
VI-DOM-A vs VITAMIN A PALMITATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinol binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription involved in cell growth, differentiation, and immune function.
Vitamin A palmitate is a retinoid that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription involved in cell growth, differentiation, and vision. It is converted to retinol and then to retinaldehyde and retinoic acid, essential for phototransduction, epithelial integrity, and immune function.
1 mL intramuscular injection once weekly; each mL contains 100,000 IU vitamin A (as retinyl palmitate) and 50,000 IU vitamin D (as ergocalciferol).
Adult: 1,500-3,000 IU (450-900 mcg RAE) orally once daily for vitamin A deficiency; IM administration not recommended due to local toxicity.
None Documented
None Documented
The terminal elimination half-life of vitamin A is 10-12 hours for retinol, but due to hepatic storage and enterohepatic recirculation, the overall body half-life can extend to 2-3 weeks with chronic dosing.
Terminal elimination half-life is approximately 7–14 days for retinol in the liver; clinical effects persist for weeks due to extensive hepatic storage.
Vitamin A is primarily excreted via bile and feces as metabolites. Renal excretion accounts for less than 5% of an oral dose. Unchanged vitamin A is not significantly excreted in urine.
Primarily hepatobiliary; >90% of retinol esters and metabolites excreted in feces via bile; less than 10% renally eliminated as water-soluble metabolites (e.g., retinoic acid glucuronides).
Category C
Category C
Vitamin A
Vitamin A